News About: Pharm. Industry
Approval of Abilify Inj makes confrontation against Janssen’s Invega
In the long-acting injectable(LAI) market for schizophrenia, which has been monopolized by Janssen with Invega Sustenna Inj, Korea Otsuka Pharmaceuticals’ Abilify Inj formed the 2-way competition as acquiring approval...
Daiichi Sankyo Korea and Daewoong announce co-promotion agreement of ‘Lixiana’Daiichi Sankyo Korea(CEO Dae-joong Kim) and Daewoong Pharmaceutical(CEO Jong-ok Lee) announced a co-promotion agreement of ‘Lixiana,’ an oral anticoagulant, on the 21st.
Daiich...
|
Hanmi Pharm reveals negotiation techniques with ‘big pharmas’Hanmi Pharm will unveil know-hows of negotiations for the large-hit new drug license agreements this year, and widely open doors to R&D for domestic biotechnology ventures havin...
|
SK Chemical-developed hemophilia treatment applied for EMA approvalA hemophilia treatment, developed by the SK Chemicals’ own technology, is about to target the foreign advanced markets.
On the 23rd, SK Chemicals(CEO Man-hoon Park) announced C...
|
Boryung Pharm challenges KRW 240 billion sales with the antihypertensive ‘Kanarb’Boryung Pharm will challenge KRW 240 sales with ‘Kanarb(antihypertensive),’ the 15th domestic new drug, by 2020.
According to Boryung Pharm, the company is planning to expand i...
|
Samsung Biologics challenges the world’s top biopharmaceutical contract manufacturer
Samsung will challenge to become the world’s largest biopharmaceutical contract manufacturer.
Samsung Biologics held the 3rd Factory Groundbreaking Ceremony with the world’s largest scale, an annual manufacturing cap...
Hanmi Pharm’s targeted lung cancer treatment is indicated as the FDA’s Breakthrough TherapyHanmi Pharm announced on the 21st that the US FDA selected HM61713(BI code name: BI1482694), developed by Hanmi Pharm, as the ‘breakthrough therapy’ of lung cancer. HM61713 is a...
|
Baekje Pharm exceeded KRW 1 trillion in sales for the first time as a single distribution companyFollowed by Geo-Young, Baekje Pharm exceeded KRW 1 trillion sales for the second time as a pharmaceutical distribution company.
President Dong-goo Kim of Baekje Pharm has recen...
|
Interests of pharmaceutical companies in health functional foods and non-pharmaceutical products
The health functional food and non-pharmaceutical product fields have become tense lately.
According to the industry concerned, a number of pharmaceutical companies have recently started to show interests in the spec...
Controversy over multinational companies’ staff reduction, “Is layoff is the only action they can make?”
While the labor-management conflict of Bayer Korea has floated, staff reductions of multinational pharmaceutical companies have also raise criticisms
Accepting the fact the staff reduction is a part of company reorga...
